Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants

NCT04504435 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
59
Enrollment
INDUSTRY
Sponsor class

Stopped Further development of GSK3494245 has been halted based on assessment of clinical data indicating that predicted efficacious doses cannot be achieved in line with dosing requirements outlined in the target product profile for the proposed indication.

Conditions

Interventions

Sponsor

GlaxoSmithKline